Sinovac’s Panflu Is First Chinese Avian Flu Vaccine Approved By SFDA
This article was originally published in PharmAsia News
SHANGHAI - Sinovac Biotech has been granted a production license for its pandemic influenza vaccine Panflu from China's State FDA, the company announced April 2. Panflu is the first vaccine approved since SFDA implemented its Special Drug Approval Procedures in 2005
You may also be interested in...
Sinovac Biotech CEO Weidong Yin recently spoke with PharmAsia News' Shanghai bureau about the Chinese vaccine market and the impact of current government policies on vaccine makers. Sinovac was established in April 2001 as a result of a joint venture between Sino Pharma, Shenzhen Kexing and Tangshan Yian. The Beijing-based company manufactured its first hepatitis A vaccine and sold its first dose in 2002. In December 2004, it was listed on the American Stock Exchange.
Researchers studying the genetic makeup of the H5N1 avian influenza virus have located the likely source of it to the Yunnan and Hunan provinces in Southern China. The strains detected in Malaysia, Thailand and Vietnam in 2002, 2003 resembled the Yunnan Province strain, they said, while the Indonesia outbreak was related to strains in Hunan during the same period. According to the scientists in a published report, poultry trade may be responsible for the strain getting to Vietnam, but a direct link from Hunan to Indonesia was not established. (Click here for more
SHANGHAI - Chinese vaccine manufacturer Sinovac Biotech will copromote its influenza vaccine Anflu with GlaxoSmithKline (China) Investment Co. under an exclusive service agreement announced Aug. 1